MX2015006333A - Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina. - Google Patents

Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.

Info

Publication number
MX2015006333A
MX2015006333A MX2015006333A MX2015006333A MX2015006333A MX 2015006333 A MX2015006333 A MX 2015006333A MX 2015006333 A MX2015006333 A MX 2015006333A MX 2015006333 A MX2015006333 A MX 2015006333A MX 2015006333 A MX2015006333 A MX 2015006333A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
melanocortin
receptor
selective agonists
formula
Prior art date
Application number
MX2015006333A
Other languages
English (en)
Other versions
MX366171B (es
Inventor
Zalfa A Abdel-Malek
Leonid Koikov
James J Knittel
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of MX2015006333A publication Critical patent/MX2015006333A/es
Publication of MX366171B publication Critical patent/MX366171B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los tri- y tetrapéptidos cortos de acuerdo con la siguiente Fórmula I Ar (CH2) mX1-X2-CO-X3-X4-X5-(Trp) n-NX6R son agonistas, selectivos, potentes del receptor de melanocortina 1 (MC1R). Se proporcionan en la presente composiciones farmacéuticas que incluyen los agonistas de péptido de la Fórmula I de MC1R y métodos para tratar enfermedades de la piel y trastornos que incluyen administrar a un individuo en necesidad del mismo una cantidad terapéutica de un péptido de la Fórmula I. Los péptidos, composiciones farmacéuticas, y métodos descritos en la presente son útiles en el tratamiento de enfermedades y trastornos que se benefician del agonismo de MC1R incluyendo melanoma, carcinoma de células basales, carcinoma de células escamosas, porfiria, erupción lumínica polimorfa, vitíligo, y urticaria solar.
MX2015006333A 2012-11-21 2013-11-20 Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina. MX366171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729018P 2012-11-21 2012-11-21
PCT/US2013/071033 WO2014081846A2 (en) 2012-11-21 2013-11-20 Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor

Publications (2)

Publication Number Publication Date
MX2015006333A true MX2015006333A (es) 2016-01-20
MX366171B MX366171B (es) 2019-07-01

Family

ID=50776668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006342A MX365620B (es) 2012-11-21 2013-11-20 Composiciones para el cuidado de la piel y metodos que comprenden agonistas selectivos del receptor de melanocortina 1.
MX2015006333A MX366171B (es) 2012-11-21 2013-11-20 Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015006342A MX365620B (es) 2012-11-21 2013-11-20 Composiciones para el cuidado de la piel y metodos que comprenden agonistas selectivos del receptor de melanocortina 1.

Country Status (7)

Country Link
US (3) US9434764B2 (es)
EP (2) EP2922565B1 (es)
AU (3) AU2013348044B2 (es)
CA (2) CA2892134C (es)
ES (2) ES2768423T3 (es)
MX (2) MX365620B (es)
WO (2) WO2014081846A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187264A1 (en) * 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
US10086035B2 (en) 2016-02-04 2018-10-02 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
JP7039814B2 (ja) * 2016-10-04 2022-03-23 ディーエスエム アイピー アセッツ ビー．ブイ． メラノコルチン－１－受容体アゴニスト
CN111182914A (zh) 2017-08-03 2020-05-19 阿拉斯廷护肤公司 用于改善皮肤松弛和身体轮廓的组合物和方法
BR112020008175A2 (pt) * 2017-10-30 2020-10-20 Dsm Ip Assets B.V. compostos inovadores
JP7296642B2 (ja) * 2018-02-27 2023-06-23 リポトゥルー，エセ．エレ． 化粧料および医薬に使用するためのペプチドおよび組成物
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
BR112022025115A2 (pt) * 2020-06-10 2023-02-07 Mitsubishi Tanabe Pharma Corp Agente profilático ou terapêutico para fotodermatose
CN116925182A (zh) * 2022-04-02 2023-10-24 肽鼎生物科技（深圳）有限公司 多肽药物及凝胶制剂的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536295A (ja) 1998-12-14 2002-10-29 パラチン テクノロジーズ， インク． 金属ペプチド組合せライブラリ及びその利用法
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CA2453515A1 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2005048967A1 (en) 2003-11-24 2005-06-02 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
EP2368562B1 (en) 2004-10-08 2015-06-17 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
CA2702169A1 (en) * 2007-10-12 2009-04-16 Decode Genetics Ehf Sequence variants for inferring human pigmentation patterns
MX356295B (es) 2008-05-27 2018-05-22 Genzyme Corp Análogos de péptido de la hormona de estimulación de alfa-melanocito.
EA021897B1 (ru) * 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1

Also Published As

Publication number Publication date
CA2892134C (en) 2022-10-04
US20180066016A1 (en) 2018-03-08
CA2892144C (en) 2020-04-28
ES2738555T3 (es) 2020-01-23
US20150297667A1 (en) 2015-10-22
WO2014081845A3 (en) 2015-07-30
EP2925340A4 (en) 2017-01-04
US10301355B2 (en) 2019-05-28
WO2014081845A2 (en) 2014-05-30
WO2014081846A3 (en) 2015-11-19
EP2922565A2 (en) 2015-09-30
EP2922565A4 (en) 2016-06-15
US9434764B2 (en) 2016-09-06
MX366171B (es) 2019-07-01
ES2768423T3 (es) 2020-06-22
AU2013348044A1 (en) 2015-06-04
AU2018204153B2 (en) 2019-04-18
WO2014081846A2 (en) 2014-05-30
CA2892134A1 (en) 2014-05-30
AU2013348043B2 (en) 2017-11-02
AU2018204153A1 (en) 2018-06-28
US9834580B2 (en) 2017-12-05
EP2925340A2 (en) 2015-10-07
EP2922565B1 (en) 2019-11-13
EP2925340B1 (en) 2019-05-08
EP2925340B8 (en) 2019-07-24
US20150299251A1 (en) 2015-10-22
MX2015006342A (es) 2016-02-25
AU2013348043A1 (en) 2015-06-04
CA2892144A1 (en) 2014-05-30
AU2013348044B2 (en) 2018-03-15
MX365620B (es) 2019-06-07

Similar Documents

Publication Publication Date Title
MX366171B (es) Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
TW201129368A (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
CA2902938C (en) Peptides for skin rejuvenation and methods of using the same
MX2011010859A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
IN2012DN06720A (es)
MX345788B (es) Nuevo tratamiento del carcinoma de prostata.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
SG10201907684PA (en) Androgen receptor modulator and uses thereof
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
WO2014151369A3 (en) Stabilized ezh2 peptides
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
WO2015081306A3 (en) Peptide tyrosinase activators
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.

Legal Events

Date Code Title Description
FG Grant or registration